Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy
NCT05778188Phase 3Recruiting
- Sponsor
- ReAlta Life Sciences
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of pegtarazimod in hypoxic-ischemic encephalopathy (HIE), sponsored by ReAlta Life Sciences. Started Jul 2023; status: recruiting.
02
Drugs
pegtarazimod
03
Conditions
hypoxic-ischemic encephalopathy (HIE)
Beyond the preview
Go deeper on NCT05778188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05778188.